Hyperuricemia is a metabolic disease
caused by impaired uric acid
(UA) metabolism. Ellagic acid (EA) is a natural small-molecule polyphenolic
compound with known antioxidative and anti-inflammatory properties.
Here, we evaluated the regulatory effects of EA on hyperuricemia and
explored the underlying mechanisms. We found that EA is an effective
xanthine oxidase (XOD) inhibitor (IC50 = 165.6 μmol/L)
and superoxide anion scavenger (IC50 = 27.66 μmol/L).
EA (5 and 10 μmol/L) treatment significantly and dose-dependently
reduced UA levels in L-O2 cells; meanwhile, intraperitoneal EA administration
(50 and 100 mg/kg) also significantly reduced serum XOD activity and
UA levels in hyperuricemic mice and markedly improved their liver
and kidney histopathology. EA treatment significantly reduced the
degree of foot edema and inhibited the expression of NLPR3 pathway-related
proteins in foot tissue of monosodium urate (MSU)-treated mice. The
anti-inflammatory effect was also observed in lipopolysaccharide-stimulated
RAW-264.7 cells. Furthermore, EA significantly inhibited the expressions
of XOD and NLRP3 pathway-related proteins (TLR4, p-p65, caspase-1,
TNF-α, and IL-18) in vitro and in vivo. Our results indicated that EA exerts ameliorative effects in experimental
hyperuricemia and foot edema via regulating the NLRP3
signaling pathway and represents a promising therapeutic option for
the management of hyperuricemia.
Context
Ferulic acid ethyl ester (FAEE) is abundant in
Ligusticum chuanxiong
Hort. (Apiaceae) and grains, and possesses diverse biological activities; but the effects of FAEE on osteoporosis has not been reported.
Objective
This study investigated whether FAEE can attenuate osteoclastogenesis and relieve ovariectomy-induced osteoporosis via attenuating mitogen-activated protein kinase (MAPK).
Materials and methods
We stimulated RAW 264.7 cells with receptor activator of NF-κB ligand (RANKL) followed by FAEE. The roles of FAEE in osteoclast production and osteogenic resorption of mature osteoclasts were evaluated by tartrate resistant acid phosphatase (TRAP) staining, expression of osteoclast-specific genes, proteins and MAPK. Ovariectomized (OVX) female Sprague-Dawley rats were administered FAEE (20 mg/kg/day) for 12 weeks to explore its potential
in vivo
, and then histology was undertaken in combination with cytokines analyses.
Results
FAEE suppressed RANKL-induced osteoclast formation (96 ± 0.88 vs. 15 ± 1.68) by suppressing the expression of osteoclast-specific genes, proteins and MAPK signalling pathway related proteins (p-ERK/ERK, p-JNK/JNK and p-P38/P38)
in vitro
. In addition, OVX rats exposed to FAEE maintained their normal calcium (Ca) (2.72 ± 0.02 vs. 2.63 ± 0.03,
p
< 0.05) balance, increased oestradiol levels (498.3 ± 9.43 vs. 398.7 ± 22.06,
p
< 0.05), simultaneously reduced levels of bone mineral density (BMD) (0.159 ± 0.0016 vs. 0.153 ± 0.0025,
p
< 0.05) and bone mineral content (BMC) (0.8 ± 0.0158 vs. 0.68 ± 0.0291,
p
< 0.01).
Discussion and conclusions
These findings suggested that FAEE could be used to ameliorate osteoporosis by the MAPK signalling pathway, suggesting that FAEE could be a potential therapeutic candidate for osteoporosis.
Benign prostatic hyperplasia (BPH) is a chronic disease that affects the quality of life of older males. Sinomenine hydrochloride (SIN) is the major bioactive alkaloid isolated from the roots of the traditional Chinese medicinal plant Sinomenium acutum Rehderett Wilson. We wondered if the SIN administration exerted a regulatory effect on BPH and its potential mechanism of action. Mice with testosterone propionate-induced BPH subjected to bilateral orchiectomy were employed for in vivo experiments. A human BPH cell line (BPH-1) was employed for in vitro experiments. SIN administration inhibited the proliferation of BPH-1 cells (p < 0.05) by regulating the expression of androgen-related proteins (steroid 5-alpha reductase 2 (SRD5A2), androgen receptors, prostate-specific antigen), apoptosis-related proteins (B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax)) and proliferation-related proteins (proliferating cell nuclear antigen (PCNA), mammalian target of rapamycin, inducible nitric oxide synthase) in vitro. SIN administration decreased the prostate-gland weight coefficient (p < 0.05) and improved the histological status of mice suffering from BPH. The regulatory effects of SIN administration on SRD5A2, an apoptosis-related protein (Bcl-2), and proliferation-related proteins (PCNA, matrix metalloproteinase-2) were consistent with in vitro data. SIN exerted a therapeutic effect against BPH probably related to lowering the SRD5A2 level and regulating the balance between the proliferation and apoptosis of cells. Our results provide an important theoretical basis for the development of plant medicines for BPH therapy.
Graphical AbstractBoth in vivo and in vitro experiments suggested that HSE may effectively lower uric acid. The mechanism might be the inhibition of XOD activity, down-regulation of TLR4-NLRP3 inflammasome and up-regulation expression of OAT1, OAT3, OCT1, OCT2 proteins.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.